Novo Nordisk celebrates first ever UN-observed World Diabetes Day

Novo Nordisk14 November is World Diabetes Day (WDD). This year is the first time that WDD is officially recognised by the United Nations. Novo Nordisk is celebrating the day with activities all over the world, from the UN building in New York to the pyramids of Egypt.

In New York, Novo Nordisk is arranging an event around the Changing Diabetes Bus, which has travelled across five continents since September 2006. And in Cairo, Novo Nordisk's Egyptian affiliate will organize diabetes walks by the pyramids and launch their own Changing Diabetes Bus.

Furthermore, Novo Nordisk will conduct special events in seven other cities: Beijing (China), Copenhagen (Denmark), Havana (Cuba), London (UK), Paris and Strasbourg (France). Here there will be Global Diabetes Walks, which put focus on an active lifestyle, human blue circles (to illustrate the UN symbol) and other external events.

"The adoption of the UN Resolution on diabetes demonstrates that all nations have recognised the severity of this worldwide pandemic. However, our engagement doesn't stop here. We have committed to work actively to help implement the Resolution on a national level by for instance continuing the Changing Diabetes Bus world tour into 2008. We will also establish high-level groups of experts to explore practical ways of improving diabetes care" says Lars Rebien Sørensen, president and CEO of Novo Nordisk.

Diabetes is a silent killer that can affect anyone at any time and is causing devastating global consequences. In 2007 diabetes is expected to cause 3.8 million deaths worldwide, almost as much as HIV/AIDS. Today 246 million people have diabetes and by 2025, the figure is expected to reach 380 million. If the trend continues at this pace diabetes will be the worst pandemic the world has ever seen by 2025.

The Resolution on diabetes was adopted by the United Nations on 20 December 2006.

For further details, please visit the World Diabetes Day website:
http://diabetesbus.novonordisk.com/Diabetes/
Diabetes-Bus/World-Diabetes-Day/world-diabetes-day-default.asp

About Novo Nordisk
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 25,800 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit www.novonordisk.com.

Most Popular Now

Bayer, Brigham and Women’s Hospital, and Massachus…

Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to ...

AstraZeneca divests rights for Losec to Cheplaphar…

AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arznei...

Cause of antibiotic resistance identified

Scientists have confirmed for the first time that bacteria can change form to avoid being detected by antibiotics in the human body. Studying samples from elderly patient...

Amgen announces positive results from two Phase 3 …

Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (2012021...

Brilinta monotherapy in high-bleeding risk patient…

New data from TWILIGHT, a Phase IV independent trial (funded by AstraZeneca), showed that in patients at high-bleeding risk who underwent PCI and completed 3 months of du...

Novartis and Microsoft announce collaboration to t…

Novartis announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science pa...

Ian Read to retire as Executive Chairman of Pfizer…

Following its regularly scheduled meeting, the Board of Directors of Pfizer Inc. (NYSE:PFE) today announced that Executive Chairman of the Board Ian C. Read has chosen to...

FDA approves first oral GLP-1 treatment for type 2…

The U.S. Food and Drug Administration today approved Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along w...

Discovery of new source of cancer antigens may exp…

For more than a decade, scientist Stephen Albert Johnston and his team at Arizona State University's Biodesign Institute have pooled their energies into an often scoffed-...

Chinese activists protest the use of traditional t…

In the West, the number of people challenging scientific authority has been growing in past decades. This has, among other things, led to a decline in the support for mas...

Cheaper drug just as effective protecting heart in…

A new clinical trial conducted at The Ohio State University Wexner Medical Center found a cost-effective generic medication works just as well as a more expensive drug in...

Dengue virus becoming resistant to vaccines and th…

Researchers from Duke-NUS Medical School (DukeNUS), in collaboration with the Agency for Science, Technology and Research (A*STAR)'s Bioinformatics Institute (BII), and t...